CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-BLA761097 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-BLA761097.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical
1

Critical

100%

0

High

0%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: LIBTAYO (CEMIPLIMAB-RWLC) — Type 1 - New Molecular Entity

Policy FDA-BLA761097 · Oncology

Critical

Cemiplimab-rwlc (Libtayo) is an intravenous injectable PD-1 inhibitor approved for oncology indications, billing under Medicare Part B as a provider-administered drug. It is reimbursed at ASP+6% under

View alert

Audit documentation

Building an audit file that includes FDA-BLA761097?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription